| Susanna Coiro, MD | |
|
2525 S Downing St, Denver, CO 80210-5817 | |
| (303) 629-2100 | |
| (303) 629-2110 |
| Full Name | Susanna Coiro |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 34 Years |
| Location | 2525 S Downing St, Denver, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548236714 | NPI | - | NPPES |
| 86429761 | Medicaid | NM | |
| Z3329 | Medicaid | UT | |
| 71687858 | Medicaid | CO | |
| 200402450A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | DR.0035299 (Colorado) | Secondary |
| 207R00000X | Internal Medicine | 35299 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Centura Health-porter Adventist Hospital | Denver, CO | Hospital |
| Littleton Adventist Hospital, Centura Health | Littleton, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Portercare Adventist Health System | 0941110886 | 547 |
News Archive
Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca.
More than 28 healthcare organizations were represented at the third Annual Integrated Provider Management (IPM) Symposium, hosted by Portico Systems. The focus of the event was how health plans are preparing for industry changes in terms of access, quality and payment reform.
Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation (GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening – an inconsistency that can have serious implications on a person's overall health and the health of their immediate family members.
BBC examines a campaign in sub-Saharan Africa that is helping to distribute drugs to prevent onchocerciasis, also known as river blindness - a disease "caused by a parasite that is spread from human to human by the black fly, which once flourished along river beds where there is fast-flowing water."
› Verified 4 days ago
| Entity Name | Inpatient Services, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710999768 PECOS PAC ID: 5496651267 Enrollment ID: O20031211000419 |
News Archive
Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca.
More than 28 healthcare organizations were represented at the third Annual Integrated Provider Management (IPM) Symposium, hosted by Portico Systems. The focus of the event was how health plans are preparing for industry changes in terms of access, quality and payment reform.
Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation (GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening – an inconsistency that can have serious implications on a person's overall health and the health of their immediate family members.
BBC examines a campaign in sub-Saharan Africa that is helping to distribute drugs to prevent onchocerciasis, also known as river blindness - a disease "caused by a parasite that is spread from human to human by the black fly, which once flourished along river beds where there is fast-flowing water."
› Verified 4 days ago
| Entity Name | Catholic Health Initiatives Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356783351 PECOS PAC ID: 8022927342 Enrollment ID: O20031215000462 |
News Archive
Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca.
More than 28 healthcare organizations were represented at the third Annual Integrated Provider Management (IPM) Symposium, hosted by Portico Systems. The focus of the event was how health plans are preparing for industry changes in terms of access, quality and payment reform.
Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation (GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening – an inconsistency that can have serious implications on a person's overall health and the health of their immediate family members.
BBC examines a campaign in sub-Saharan Africa that is helping to distribute drugs to prevent onchocerciasis, also known as river blindness - a disease "caused by a parasite that is spread from human to human by the black fly, which once flourished along river beds where there is fast-flowing water."
› Verified 4 days ago
| Entity Name | Portercare Adventist Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760761928 PECOS PAC ID: 0941110886 Enrollment ID: O20090115000327 |
News Archive
Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca.
More than 28 healthcare organizations were represented at the third Annual Integrated Provider Management (IPM) Symposium, hosted by Portico Systems. The focus of the event was how health plans are preparing for industry changes in terms of access, quality and payment reform.
Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation (GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening – an inconsistency that can have serious implications on a person's overall health and the health of their immediate family members.
BBC examines a campaign in sub-Saharan Africa that is helping to distribute drugs to prevent onchocerciasis, also known as river blindness - a disease "caused by a parasite that is spread from human to human by the black fly, which once flourished along river beds where there is fast-flowing water."
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Susanna Coiro, MD 2525 S Downing St, Denver, CO 80210-5817 Ph: (303) 715-7184 | Susanna Coiro, MD 2525 S Downing St, Denver, CO 80210-5817 Ph: (303) 629-2100 |
News Archive
Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca.
More than 28 healthcare organizations were represented at the third Annual Integrated Provider Management (IPM) Symposium, hosted by Portico Systems. The focus of the event was how health plans are preparing for industry changes in terms of access, quality and payment reform.
Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation (GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening – an inconsistency that can have serious implications on a person's overall health and the health of their immediate family members.
BBC examines a campaign in sub-Saharan Africa that is helping to distribute drugs to prevent onchocerciasis, also known as river blindness - a disease "caused by a parasite that is spread from human to human by the black fly, which once flourished along river beds where there is fast-flowing water."
› Verified 4 days ago
Katrina Wagoner-hursh, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1835 Franklin St, Denver, CO 80218 Phone: 303-338-4545 | |
Emily Martin Jones, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 8111 E Lowry Blvd, Denver, CO 80230 Phone: 720-848-0000 | |
Dr. Jesus Heliodoro Hermosillo Rodriguez, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2045 N Franklin St, Denver, CO 80205 Phone: 303-338-4545 | |
Margaret Hay, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1601 E 19th Ave Ste 3100, Denver, CO 80218 Phone: 303-863-0300 Fax: 303-863-7014 | |
Dr. Alan W Burgess, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1601 E 19th Ave Ste 6000, Denver, CO 80218 Phone: 303-861-7001 Fax: 303-861-8624 | |
Dr. Sahibzada Mohsin Shah, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 777 Bannock St, Denver, CO 80204 Phone: 303-436-6000 | |
Shyam M Parkhie, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 130 Rampart Way, 300b, Denver, CO 80230 Phone: 720-343-1562 Fax: 720-343-1563 |